Gelonghui May 11 丨 Shanghai Kaibao (300039.SZ) held a performance briefing on May 10, 2024 to discuss “How is Youxinding progressing?” The company replied that according to the information publicly released by the Drug Evaluation Center of the State Drug Administration, the project has entered phase III clinical research.
上海凯宝(300039.SZ)：优欣定项目已进入III期临床研究阶段
Shanghai Kaibao (300039.SZ): The Youxinding Project has entered phase III clinical research
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.